Cambridge-based pharmaceutical company Millennium and their parent company Takeda Pharmaceutical, based in Japan, report they have submitted two supplemental new drug applications (NDAs) to the FDA for Velcade, a cancer treatment, according to Mass High Tech.

The first NDA seeks to add a subcutaneous route of administration for the drug; the second is for using Velcade in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma. Velcade is currently is approved for intravenous use in patients with multiple myeloma and mantle cell lymphoma.

The NDAs are part of Millenium’s efforts to expand on the drug administration and use in additional cancers, says the company’s chief medical officer Nancy Simonian.